Rexahn Pharmaceuticals to Present data on the Mechanism of action of RX-5902: A first-in-class inhib

Rexahn Pharmaceuticals to Present data on the Mechanism of action of RX-5902: A first-in-class inhibitor of p68 helicase for the treatment of solid tumors at AACR Annual Meeting 2013

ROCKVILLE, Md.--(BUSINESS WIRE)-- Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing potential best-in-class oncology therapies, today announced that it will present mechanism of action data on RX-5902 during a poster session at the American Association for Cancer Research (AACR) 104th Annual Meeting being held in Washington, DC, April 6-10, 2013, at the Washington Convention Center.

The Company will present the mechanism data of RX-5902 in a poster (abstract #5507) entitled, "Mechanistic study of a new 4-(3, 5-dimethoxyphenyl)-N-(7-fluoro-3-methoxyquinoxalin-2-yl)piperazine-1-carboxamide compound (RX-5902)," on Wednesday, April 10, 2013, during the "Chemotherapy and Cancer Dependencies" poster session from 8:00 am - 12:00 pm EDT in Exhibit Hall A-C, Poster Section 37.

For more information on the AACR conference, please visit

About RX-5902

RX-5902 is an orally bioavailable, first-in-class inhibitor of p68 RNA helicase for the treatment of various solid tumors, such as melanoma and cancers of the ovary, kidney and pancreas. Rexahn has filed an IND for RX-5902 and anticipates initiating Phase I clinical development in the second quarter of 2013.

RX-5902 has been shown to produce potent anti-tumor effects, increased survival in xenograft models, anti-proliferative activity in drug-resistance cancer cell lines and synergistic effects with known anti-cancer drugs.

RX-5902 is part of a growing pipeline of clinical stage oncology compounds that Rexahn is developing to potentially provide improved efficacy and reduced toxicity, resulting in improved survival and quality of life for patients.

About Rexahn Pharmaceuticals, Inc.

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing best-in-class therapeutics for the treatment of cancer. Rexahn currently has three clinical stage oncology candidates, Archexin®, RX-3117, and RX-5902 and a robust pipeline of preclinical compounds to treat multiple types of cancer. Rexahn has also developed proprietary drug discovery platform technologies in the areas of nano-medicines, 3D-GOLD, and TIMES. For more information, please visit

Safe Harbor

To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about Rexahn's plans, objectives, expectations and intentions with respect to future operations and products and other statements identified by words such as "will," "potential," "could," "can," "believe," "intends," "continue," "plans," "expects," "anticipates," "estimates," "may," other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause Rexahn's actual results to be materially different than those expressed in or implied by Rexahn's forward-looking statements. For Rexahn, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of Rexahn's licensees or sublicensees; the success of clinical testing; and Rexahn's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect Rexahn's actual results are described in Rexahn's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. Rexahn undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Allen & Caron Inc.
Michael Mason, 212-691-8087
Base Pair Group
Constantine Theodoropulos, 617-816-4637

KEYWORDS: United States North America Maryland


The article Rexahn Pharmaceuticals to Present data on the Mechanism of action of RX-5902: A first-in-class inhibitor of p68 helicase for the treatment of solid tumors at AACR Annual Meeting 2013 originally appeared on

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.